Exane Asset Management Gilead Sciences, Inc. Transaction History

Exane Asset Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 24, 2019	SELL	$62.51 - $69.0 $3.13 Million - $3.45 Million	-50,013 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$61.87 - $69.38 $124,544 - $139,661	2,013 Added 4.19%	50,013 $0
Q1 2019 May 07, 2019	BUY	$62.53 - $70.05 $1.64 Million - $1.83 Million	26,169 Added 119.87%	48,000 $0
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $9.85 Million - $12.8 Million	-162,624 Reduced 88.16%	21,831 $1.37 Million
Q3 2018 Nov 16, 2018	BUY	$71.28 - $78.92 $11.8 Million - $13.1 Million	166,055 Added 902.47%	184,455 $0

Q2 2018 Sep 06, 2018	SELL	$64.88 - $75.68 $950,751 - $1.11 Million	-14,654 Reduced 44.33%	18,400 $0
Q1 2018 Apr 30, 2018	SELL	$72.84 - $88.8 $18.2 Million - $22.2 Million	-249,492 Reduced 88.3%	33,054 $0
Q4 2017 Feb 08, 2018	SELL	$71.15 - $83.52 $19.7 Million - $23.1 Million	-277,041 Reduced 49.51%	282,546 $0
Q3 2017 Oct 13, 2017	BUY	$72.11 - $85.47 $40.4 Million - $47.8 Million	559,587	559,587 $45.3 Billion

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $84.9B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.